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Facilitate Public Protections Against Tuberculosis 
Abstract 
Background: 
Economic modeling and analysis can facilitate evidence-based policy and practice. Such analyses may 
exceed the technical capacity and mission of public health agencies, yet may be critical to sustain health 
protections such as tuberculosis (TB) control. The net effect of TB prevention is incompletely understood, 
hampering objective value judgments of national TB elimination policies. This may promote inefficiencies 
and threaten individual and public health protections. 
We describe how a HRSA-funded Texas Public Health Training Center (TPHTC) coordinated specialized 
analytical skills with the needs of a state public health department to create a user-friendly tool to inform 
planning and resource allocation; and to identify risks, benefits, opportunities, and value in the context of 
Texas’ Department of State Health Services (TDSHS) TB control programs. 
Methods: 
Key informants within TDSHS and faculty from the University of North Texas Health Science Center 
(UNTHSC) and its associated TPHTC collaborated to develop a combined health, cost, and outcome 
model to answer questions of interest to TDSHS. The model incorporates standard techniques, TB 
specific logic and data, and Texas specific population, epidemiologic, and programmatic data into a 
Microsoft Excel platform. Outcome measures include 2013 USD costs from a public agency perspective 
and health losses denominated in Quality Adjusted Life Years (QALYs) (but not assigned a dollar value). 
Outcomes represent the 10-year accrued net present value (NPV) of variable costs associated with each 
incident TB case. The model used only publicly available, non-confidential data. 
Results: 
Under current public TB prevention and control practices we estimate public spending for acute medical 
care and health losses for Texas’ 1325 TB cases in 2011 will exceed a NPV $100,000,000 and 4800 
QALYs by 2022; societal costs would likely be much higher. Public TB control is relatively cost effective 
and preserves 3.7 QALYs/case averted at $54,000/QALY. 
Implications: 
Partnerships between academic institutions and public health departments offer the potential to produce 
the economic analyses needed for judicious use of public resources. We used accessible methods, data, 
and technology to create a model to analyze the relative value of public TB control in Texas as well as to 
identify potential efficiencies within activities. Our analysis suggests public efforts against latent TB 
infection effectively and efficiently mitigate some of the substantial health and cost impact of TB to 
Texas. Most of TB’s burden remains, however, and more careful targeting of prevention by risk promises 
rich rewards. 
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METHODS: 
 
Between January and April 2013, key TDSHS informants worked with faculty from the University of 
North Texas Health Science Center (UNTHSC) and its associated TPHTC to develop a combined 
health, cost, and outcome model to answer two questions of interest to TDSHS. The first identifies 
‘global value’ of TB prevention--what potentially preventable economic and disease burden does TB 
create to Texas?  The second identifies ‘programmatic value’ in prevention--which of the various 
diagnostic and treatment combinations potentially offer the most efficient TB prevention in current 
practice? 
 
Collaborators met weekly to design and inform the model and then vet its validity, function, 
performance, and relevance.  The final model incorporates previously published methodologies for 
the study of TB cost with standard techniques for economic analyses in healthcare in a Microsoft 
Excel platform, and includes both TB specific logic and publicly available Texas specific population, 
epidemiologic, and programmatic data.1,2   Within a TB infected population, potential outcomes are 
a function of risk, cost, and natural history.  The model uses a semi-Markov process to consider 
these, then to estimate and compare cost and effect among various circumstances or planned action.  
 
The model was created for public health agencies and allows users to readily update or change its 
assumptions. It also allows users to compare large or small differences in epidemiology, treatment, 
public policy, technology, cost, and many other factors, or to conduct sensitivity analyses. The 
resulting tool calculates the potential number of preventable TB cases and their associated economic 
burden, and informs diagnostic and treatment decisions to prevent the most TB cases for the 
greatest value.  
We assume prevention “value” to be the costs averted by preventing an incident case, quantified as 
the 10-year accrued net present value (NPV) of individual health losses and public agency spending 
associated with an incident TB case.  Healthcare costs are given in 2013 U.S. dollars (USD), and 
reflect costs incurred by the public health system to treat a patient; health losses were enumerated in 
Quality Adjusted Life Years (QALYs); both cost and health outcomes are discounted at 3% per 
annum where appropriate.3 Relative value given varied factors is given as the incremental cost 
effectiveness ratio (ICER) for the change scenario when compared to baseline.  Global value of 
public investment in TB prevention was estimated relative to a counterfactual scenario in which the 
public activities do not take place.  Private systems do not typically conduct surveillance and 
prevention efforts similar to those of interest in this simulation and we assume no change in private 
health system activities.  
 
RESULTS: 
 
In 2011, 1,325 new cases of active TB were reported among Texans. We estimate the costs to public 
payers associated with these cases will exceed $100,000,000 by 2022; costs to all payers —i.e., 
“societal costs”-- would likely be much higher (Table 1).  Further, we estimate the 10-year burden of 
associated morbidity and mortality stemming from those cases will result in health losses exceeding 
4,800 QALYs.  These opportunity costs suggest that on average each successfully prevented TB case 
would avert a respective $82,000 and 3.7 QALYs of publicly funded acute healthcare spending and 
health loss (Table 1).   
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Table 1: Model predicted 10-year net health loss and agency variable cost of care associated with incident TB, 
Texas 2011 (1325 cases) 
  
Clinical event 2011 TX 
incidence 
Events/ 
base case 
Cost/ 
event 
Cost/ 
base case  
Statewide cost 
Variable cost components             
Uncomplicated tuberculosis outpt course of care 1,209 0.91 $7,046 $6,429 $7,772,833 
Tuberculosis/HIV co-infection 
(TB-HIV) outpt course of care 100 0.08 $8,760 $661 $876,000 
Multi-drug resistant tuberculosis 
(MDR TB) (HIV + or -) outpt course of care 16 0.01 $48,491 $586 $775,856 
Contact, case outpt course of care 10,415 7.86 $603 $4,737 $6,276,467 
Contact, suspect outpt course of care 10,136 7.65 $478 $3,653 $4,840,477 
High-probability (HP) suspect outpt course of care 1,365 1.03 $3,253 $3,351 $4,439,532 
Hospitalization day inpt day 19,593 11.60 $1,350 $15,656 $26,443,449 
Secondary Transmission Secondary TB case 1,297 1.20 $39,516 $47,419 $51,269,300 
Variable cost 1 TB case 1,325     $82,491 $102,693,915 
Health outcome components             
Death during treatment 
discounted QALY, 
10-year sum 152 0.05     152 
Pulmonary impairment after TB1 
discounted QALY, 
10-year sum 1,692 2.36     1692 
Acute illness/treatment discounted QALY 331 0.25     331 
Disproportionate death after 
treatment4 
discounted QALY, 
10-year sum 2,686 2.03     2686 
Health losses 
discounted QALY, 
10-year sum         4861 
 
 
Analysis of return on investment and cost-effectiveness of TB surveillance and prevention from a 
public payer perspective predicts public spending prevents incident TB at a cost of $257,000 per 
case, a 10-year net loss of (-)$1,380 per preventive treatment provided (data not shown).   
 
These results indicate that Texas’ current TB screening and treatment practices are relatively efficient 
in producing health, with the cost of $54,000 per QALY considered acceptable by health economists 
(Table 2). Sensitivity analyses were conducted to identify cost and outcome ‘drivers’ in the model 
and to predict potentially efficient program strategies.  Many such efficiencies exist.  For instance, a 
50% improvement in targeted screening programs (e.g. same number of diagnoses with half the 
screenings) would reduce the net spending loss for preventive treatments to less than $500 and 
decrease the price per QALY to $29,000. Targeting surveillance to populations with 15% LTBI 
prevalence would yield a further 50% improvement in screening detection, avert TB for 
$66,000/case, and provide a positive net return on investment ($38) per preventive treatment. 
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Table 2: Health outcomes and costs in Texas associated with 
tuberculosis according to current screening and treatment practices 
 No screening 
or treatment 
Current standard 
of care * 
Total number 30,948 24,225 
Total prevention program cost $0 $46,327,289 
Predicted TB incidence over 10 
years 
674 494 
TB Cases averted over 10 years  0 180 
Deaths attributable to TB over 
10 years 
32.49 23.82 
Net life years lost over 10 years 
due to TB 
244.67 179.42 
QALYs lost over 10 years due 
to TB illness and mortality 
1158.97 849.88 
QALY loss prevented over 10 
years   
0 309.09 
Average cost per TB case 
averted 
n/a $257,857 
Average cost per QALY saved n/a $54,511 
 
* Screening by tuberculin skin test with 9 months of isoniazid for TB prevention where indicated 
 
 
IMPLICATIONS 
 
Robust and integrated data and the analyses they inform are necessary to optimize public health 
protections, and this project suggests how academic/practitioner partnerships using these can 
provide a roadmap to best practices.   We created and provided an accessible, objective, Microsoft 
Excel-based model to explore the cost-effectiveness of TB control in Texas. We then used relevant 
local data to answer questions of interest to health authorities and reported findings to Texas 
Department of State Health Services’ executive leadership and to its TB elimination division.  Even 
given our limited analytical perspective and assumptions of generally loose targeting, TB 
prevention—proactive public interventions to prevent asymptomatic, non-communicable latent TB 
infection from progression to active, communicable TB disease—is not only effective but a “good 
buy” by the standards of health economists.  
 
Prevention interventions should include carefully targeting screening to populations at greatest risk 
for TB infection, and/or which have factors that increase risk for progression from latent to active 
TB. Under current screening protocols, about 2% of screenings result in positive diagnoses—far 
below the estimated statewide prevalence estimate of nearly 5%. When modeled under current 
program activity assumptions, approximately two-thirds of the theoretically preventable health loss 
attributable to TB remains. This indicates what gains remain to be realized before the full potential 
of prevention is attained by interventions to increase adherence to preventive therapies, for instance.  
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Positive financial returns to the system making healthcare investments are very rare, as is health 
department capacity to conduct the analyses that would identify these--or even to guide judicious 
use of public resources. It is striking that our relatively brief and inexpensive collaboration between 
academia and state health authorities identified routine protections against TB as effective and cost 
effective.  Continued efforts to improve TB prevention through evidence-based advocacy, more 
objective program or population targeting, and enhanced risk control should be a priority and may 
be well rewarded with greater efficiencies, improved population health, and even cost savings.  
 
 
SUMMARY BOX: 
 
What is Already Known about This Topic?  Much is known about the natural 
history, treatments and their costs, and acute health losses associated with active 
tuberculosis.  Much less is known about the costs and benefits of TB prevention, 
leaving it difficult for health authorities to objectively judge the relative value of 
pursuing prevention as a matter of practice or policy in their context.  Barriers exist 
to effective consideration of these unanswered questions by either academic or 
public health entities alone. 
 
What is Added by this Report?  We describe a health department/academic 
collaboration to build a versatile and context-sensitive modeling tool using publicly 
available data and common software, and its use to inform statewide public resource 
allocation decisions. Governmental public health agencies can be a valuable resource 
for population-level data and existing mechanisms for reaching communities with 
the greatest needs. Targeted prevention efforts can maximize the use of scarce public 
health resources to result in the full potential of prevention efforts. 
 
What are the Implications for Public Health Practice, Policy, and Research?  
Applied economic analysis is an accessible, relevant, and often very useful strategy to 
facilitate and support key health authority activities, and the careful coordination of 
academic skills with practitioner perspectives can be an effective means to conduct 
such analyses. 
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